RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that three senior management team members across clinical development and research have joined the company.
- Susan Moran, M.D., M.S.C.E. – Chief Medical Officer. With over 20 years of clinical experience in industry and academia, Susan has successfully led programs from IND clearance to full regulatory approval. Prior to RayzeBio, Susan led the clinical efforts that led to FDA approval of Truseltiq for cholangiocarcinoma.
- Kimberly Ma, M.S. – Senior Vice President of Clinical Operations. Kim has vast experience in clinical operations having spent over 17 years in CRO, pharmaceutical and biotech companies leading efforts in oncology clinical trials from Phase 1 to Phase 3. Most recently, she oversaw a global Phase 3 program in breast cancer.
- Nicholas Smith, Ph.D. – Senior Vice President of Chemistry Innovation. For over 20 years, Nick has developed small molecules across multiple therapeutic areas with a particular interest in oncology. He has led the discovery and development of several novel cancer therapies that have entered clinical evaluation and have progressed to approval.
“I am thrilled to have Susan, Kim and Nick join our efforts to discover, develop and ultimately commercialize innovative radiopharmaceutical products for cancer,” said Ken Song, M.D., President and CEO of RayzeBio. “Each of them has had successful careers in their respective disciplines and will undoubtedly propel us to the next phase of our company’s growth.”
Dr. Moran further added, “I am incredibly excited to join this outstanding team to help move RayzeBio’s investigational therapies into the clinic. As a field, we’ve witnessed the clinically meaningful impact that radiopharmaceuticals can have, and I am very optimistic that this next generation of potent, targeted radiopharmaceuticals will provide further benefits for patients living with cancer.”
About RayzeBio
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005015/en/
Contacts
Ken Song, M.D.
info@rayzebio.com
